Gracell Closes $100 Million C Funding for Novel CAR-T Technologies

Gracell Bio, a Suzhou CAR-T company, closed a $100 million Series C funding to develop products that address the major problems facing CAR-T therapies: high cost and manufacturing time. The company has developed two technologies, FasTCAR and TruUCAR, which offer next-day manufactured or off-the-shelf CAR-T therapies. One candidate from each technology has started investigator-led studies in China . In 2019, Gracell completed an $85 million Series B round. The company's latest fundraising was led by Wellington Management Company, OrbiMed and Morningside Ventures. More details.... Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.